1. Home
  2. FLO vs CRVS Comparison

FLO vs CRVS Comparison

Compare FLO & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flowers Foods Inc.

FLO

Flowers Foods Inc.

HOLD

Current Price

$6.17

Market Cap

1.5B

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$13.24

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLO
CRVS
Founded
1919
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
2000
2016

Fundamental Metrics

Financial Performance
Metric
FLO
CRVS
Price
$6.17
$13.24
Analyst Decision
Hold
Strong Buy
Analyst Count
5
6
Target Price
$11.20
$30.17
AVG Volume (30 Days)
6.5M
649.1K
Earning Date
05-15-2026
05-07-2026
Dividend Yield
11.16%
N/A
EPS Growth
N/A
48.04
EPS
0.39
N/A
Revenue
$5,256,479,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.65
N/A
P/E Ratio
$16.21
N/A
Revenue Growth
3.00
N/A
52 Week Low
$6.10
$5.64
52 Week High
$14.41
$26.95

Technical Indicators

Market Signals
Indicator
FLO
CRVS
Relative Strength Index (RSI) 27.88 37.61
Support Level N/A $12.76
Resistance Level $8.86 $14.00
Average True Range (ATR) 0.30 0.62
MACD -0.08 -0.13
Stochastic Oscillator 5.94 8.89

Price Performance

Historical Comparison
FLO
CRVS

About FLO Flowers Foods Inc.

Flowers Foods Inc operates as a producer and marketer of packaged bakery foods in the United States. Its principal products include breads, buns, rolls, snack items (bars, cakes, cookies, and crackers), bagels, English muffins, tortillas, and baking mixes. These products are sold under the brand names Nature's Own, Dave's Killer Bread (DKB), Canyon Bakehouse, Simple Mills, Wonder, and Tastykake. The company derives the majority of its revenue from the sales of its bakery products.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: